MarketFriction

Caplin Point Laboratories Ltd

NSE CAPLIPOINT · BSE 524742 · Pharmaceuticals
₹2,631.90 -3.11%
NSE close2026-10-01
52 week range1,500.30 - 2,990.00
Market cap₹20,858 Cr.
P/E31.4
Nifty 500Smallcap 250 Price band 20% Delivery 43.6%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales410436453459483493502510534543600610
Expenses273293308307318331334332345353396397
Operating Profit137142145152165162168178189190204213
OPM %34%33%32%33%34%33%33%35%35%35%34%35%
Other Income211717192131262330342834
Interest000000000000
Depreciation121416161716171618191922
Profit before tax146145146154168177177184201204213225
Tax %20%18%17%19%22%21%18%18%20%19%19%20%
Net Profit116120121125131140145151160166173179
EPS in Rs15.1315.4316.0116.3117.2118.2818.7620.1020.3221.5622.3823.27
Mar 2016 9mMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales2394025406498631,0611,2691,4671,6941,9372,1872,287
Expenses1752763454176037328741,0251,1421,2871,4221,491
Operating Profit64125195232260329395442552651765797
OPM %27%31%36%36%30%31%31%30%33%34%35%35%
Other Income4101319412338556692111126
Interest011102111111
Depreciation71319233237474553667378
Profit before tax60121188227269314386451564677803844
Tax %24%21%23%22%20%20%20%16%18%20%19%
Net Profit4696145177215251308377461541650678
EPS in Rs6.0512.6519.1523.3528.4232.0339.5649.5760.1970.5684.3687.53
Dividend Payout %20%12%10%9%9%9%10%9%8%8%9%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth25%16%14%15%
Compounded Profit Growth30%21%19%18%
Stock Price CAGR27%26%39%40%
Return on Equity25%23%22%21%
Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital151515151515151515151515
Reserves781132103495828589541,2521,6492,0842,6193,355
Borrowings221136113235219222219222221
Other Liabilities134137133136109139159250305380352446
Total Liabilities2292673585007431,1261,3641,7362,1912,6983,2084,038
Fixed Assets113144152169227272305287280453546580
CWIP31031510201418221117144234
Investments00174770611189281376590859
Other Assets851221862694367721,0331,3431,4101,7531,9282,365
Total Assets2292673585007431,1261,3641,7362,1912,6983,2084,038
Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity504268668345269337271318432523
Cash from Investing Activity-23-6-36-69-100-54-30-377-216-319-333-582
Cash from Financing Activity-9-14-7-129080-24-41-28-38-38-46
Net Cash Flow192325-147370215-8127-3961-105
Free Cash Flow2434431818-3219524678173241275
CFO/OP103%92%73%53%54%38%102%106%81%77%86%87%
Jun 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days81230859097969198117119138
Inventory Days3757444447210139149159183159181
Days Payable11216815514476576810284116103125
Cash Conversion Cycle-67-99-81-1661251166138173184175194
Working Capital Days-128-114-2947104167145165144166174199
ROCE %68%62%68%63%45%33%28%28%26%26%26%24%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters70.62%70.62%70.62%70.56%70.56%70.56%70.56%70.56%70.57%70.57%70.57%70.57%
FIIs3.09%2.84%3.33%3.38%3.71%4.86%5.73%6.16%6.51%6.58%6.15%5.76%
DIIs0.21%0.43%1.08%1.49%1.83%2.11%2.00%2.22%2.10%2.05%2.14%2.49%
Public26.08%26.11%24.95%24.59%23.93%22.48%21.72%21.06%20.82%20.81%21.14%21.19%
No. of Shareholders78,06879,43881,40980,41196,12392,70296,38794,16993,75393,70593,89694,385

Fundamentals

Market Cap₹ 20,858 Cr.
Current Price₹ 2,744
Stock P/E31.4
Book Value₹ 443
ROCE24.2 %
ROE20.9 %
Dividend Yield0.29 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)15%
Compounded Profit Growth (TTM)18%
Consolidated figures.
Valuation
Market capRs 20,006 Cr
Enterprise valueRs 19,606 Cr
P/E (TTM)30.07x
Price to book5.94x
Price to sales8.75x
EV / EBITDA21.25x
EV / EBIT23.22x
EV / sales8.57x
Price to cash flow38.23x
Earnings yield3.33%
Dividend yield0.30%
P/E, 3-year average22.68x
P/B, 3-year average4.64x
P/E, 5-year average19.44x
P/B, 5-year average4.14x
Profitability
Operating margin (excl. other income)34.98%
Operating margin (incl. other income)40.07%
EBITDA margin40.33%
Pre-tax margin36.88%
Net profit margin29.09%
Net margin, latest quarter28.98%
ROE21.36%
ROCE24.93%
ROA17.70%
ROE, 3-year average22.77%
ROCE, 3-year average26.00%
ROA, 3-year average18.19%
ROE, 5-year average24.16%
ROCE, 5-year average26.71%
ROA, 5-year average18.61%
ROIC (approx.)23.01%
Tax rate19.07%
Other income / net worth3.31%
Growth
Sales growth (latest year)12.89%
Profit growth (latest year)19.57%
Sales CAGR, 3 years14.25%
Sales CAGR, 5 years15.56%
Profit CAGR, 3 years19.45%
Profit CAGR, 5 years21.49%
Sales growth QoQ1.70%
Profit growth QoQ4.00%
Sales growth YoY (latest quarter)19.63%
Profit growth YoY (latest quarter)15.78%
Per share
EPS (TTM)Rs 87.53
EPS (latest year)Rs 84.36
EPS (latest quarter)Rs 23.27
EPS, 3-year averageRs 71.70
EPS, 5-year averageRs 60.85
Book value per shareRs 443.33
Sales per shareRs 300.92
Cash flow per shareRs 68.84
Free cash flow per shareRs 36.18
Dividend per share (latest year)Rs 8.00
Dividend per share, 3-year averageRs 6.33
Dividend per share, 5-year averageRs 5.50
Dividends
Dividend payout9.48%
Dividend payout, 3-year average8.76%
Dividend payout, 5-year average9.10%
Efficiency
Asset turnover0.54x
Fixed asset turnover3.77x
Inventory turnover2.24x
Inventory days163 days
Debtor days138 days
Debtors turnover2.65x
Creditor days125 days
Cash conversion cycle194 days
Working capital days199 days
Leverage
Total debtRs 221 Cr
Cash and bankRs 621 Cr
Net debtRs -400 Cr
Debt to equity0.07x
Net debt / EBITDA-0.43x
Interest coverage959.58x
Current ratio (filing 2026-03-31)6.70x
Quick ratio (filing 2026-03-31)5.59x
Trade payables (filing 2026-03-31)Rs 296 Cr
Owners' fund to total sources83.46%
Debt to assets5.48%
Cash flow
Cash from Operating Activity (latest year)Rs 523 Cr
Cash from Investing Activity (latest year)Rs -582 Cr
Cash from Financing Activity (latest year)Rs -46 Cr
Net Cash Flow (latest year)Rs -105 Cr
Free cash flow (latest year)Rs 275 Cr
FCFE (approx.: FCF + change in debt)Rs 275 Cr
Cash from ops / profit, 5 years0.80x
Sales to cash flow4.18x
Statement figures
Net sales (TTM)Rs 2,287 Cr
Net sales (latest year)Rs 2,187 Cr
Sales (latest quarter)Rs 610 Cr
Operating profit excl. other income (latest year)Rs 765 Cr
Operating profit (latest quarter)Rs 213 Cr
Other income (TTM)Rs 126 Cr
EBITDA (TTM)Rs 923 Cr
PBDT (TTM)Rs 922 Cr
Profit before tax (TTM)Rs 844 Cr
Tax (latest year)Rs 153 Cr
Net profit (TTM)Rs 665 Cr
Net profit (latest year)Rs 641 Cr
Net profit (latest quarter)Rs 177 Cr
Depreciation (TTM)Rs 78 Cr
Depreciation (latest quarter)Rs 22 Cr
Interest (TTM)Rs 1 Cr
Cost of goods sold (latest year)Rs 962 Cr
Total expenditure (latest year)Rs 1,422 Cr
Total income (latest year)Rs 2,299 Cr
Share capitalRs 15 Cr
ReservesRs 3,355 Cr
Shareholders' fundsRs 3,370 Cr
Total assetsRs 4,038 Cr
Net blockRs 580 Cr
Capital work in progressRs 234 Cr
InvestmentsRs 859 Cr
ReceivablesRs 826 Cr
InventoryRs 429 Cr
Other liabilitiesRs 446 Cr
Shares outstanding (crore)7.60
Ownership
Promoter holding70.57% (+0.01 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 30.1 is at the 81th percentile of its own 9.4-year range (median 22.1, low 11.0, high 54.9).
P/B 5.94 is at the 57th percentile (median 5.73).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodCAPLIPOINTNifty 50Difference
1 week-8.2%-2.8% -5.4 pts
1 month-2.9%-6.8% +3.9 pts
3 months+3.7%-7.6% +11.3 pts
6 months+74.9%+0.4% +74.5 pts
1 year+20.5%-9.9% +30.4 pts
2 years+38.2%-13.6% +51.8 pts
3 years+155.3%+14.2% +141.1 pts
5 years+200.1%+27.9% +172.2 pts
44 mutual fund schemes hold about ₹310 Cr. Over three months 8 bought more and 35 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
UTI Small Cap Fund1.67%88 -15%
UTI Large & Mid Cap Fund1.06%69 -21%
UTI Aggressive Hybrid Fund0.78%53 -28%
UTI Healthcare Fund3.05%44 -27%
UTI Retirement Fund0.46%22 -25%
Nippon India Nifty Smallcap 250 Index Fund0.23%8 -11%
SBI Nifty Smallcap 250 Index Fund0.23%4 -11%
Quantum Small Cap Fund1.57%4 -15%
Motilal Oswal Nifty Smallcap 250 Index Fund0.23%3 -11%
Edelweiss Nifty500 Multicap Momentum Quality 50 Index Fund0.37%2 +100%
ICICI Pru Nifty Smallcap 250 Index Fund0.23%2 -11%
HDFC NIFTY Smallcap 250 Index Fund0.23%2 -11%
The Wealth Company Small Cap Fund1.62%2 +100%
ITI Pharma & Healthcare Fund0.61%2 -1%
Nippon India Nifty 500 Equal Weight Index Fund0.19%1 -14%
JioBlackRock Nifty Smallcap 250 Index Fund0.23%1 -11%
Motilal Oswal Nifty 500 Index Fund0.03%1 -11%
The Wealth Company Balanced Advantage Fund1.42%1 +100%
Edelweiss Nifty Smallcap 250 Index Fund0.23%1 -11%
UTI Nifty Midsmallcap 400 Momentum Quality 100 Index Fund0.25%0 +32%
Groww Nifty Smallcap 250 Index Fund0.23%0 -11%
HDFC Nifty500 Multicap 50:25:25 Index Fund0.06%0 -10%
Navi Nifty Smallcap250 Momentum Quality 100 Index Fund0.65%0 +32%
Bandhan Nifty Smallcap 250 Index Fund0.23%0 -11%
SBI Nifty 500 Index Fund0.03%0 -11%

Red flags

F-score 5 of 8
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Insider trades

NSE insider and takeover-code disclosures
DateWhoRoleSideSharesValueHow
2023-03-23P VijayalakshmiPromoter Groupother898,790Rs 54.74 CrGift
2021-11-23Satish KrishnanEmployees/Designated Employesell5,000Rs 0.41 CrMarket Sale
2021-11-22Arulsudar NatrajanEmployees/Designated Employesell1,500Rs 0.12 CrMarket Sale
2021-11-22Arulsudar NatrajanEmployees/Designated Employesell2,000Rs 0.17 CrMarket Sale
2021-11-17Subramanian NarayanaswamyEmployees/Designated Employesell100Rs 0.01 CrMarket Sale
2021-11-17Arulsudar NatrajanEmployees/Designated Employesell1,500Rs 0.13 CrMarket Sale
2021-11-17Subramanian NarayanaswamyEmployees/Designated Employesell4,900Rs 0.43 CrMarket Sale
2021-11-02Sudhakar NEmployees/Designated Employeother3,333Rs 0.00 CrESOP
2021-11-02Sundar MEmployees/Designated Employeother1,667Rs 0.00 CrESOP
2021-11-02Umesh ShettyEmployees/Designated Employeother8,333Rs 0.00 CrESOP
2021-11-02Vamsee Krishna TataEmployees/Designated Employeother2,500Rs 0.00 CrESOP
2021-11-02Venkatachalam PEmployees/Designated Employeother3,333Rs 0.00 CrESOP
Latest disclosed trades by insiders, promoters and large holders. Grants, option exercises and pledges show as "other". A filing is a fact, not a signal on its own.

Latest quarter

Jun 2026
Sales ₹610 Cr +19.6% vs Jun 2025. Net profit ₹179 Cr +18.5%.
Against our estimate for Jun 2026: sales +4.2%, profit +2.6% beat. Our estimate for Sep 2026: sales Rs 638 Cr, profit Rs 189 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-09-18Dividend - Rs 4 Per Share
2026-05-29Interim Dividend - Rs 4 Per Share
2025-09-12Dividend - Rs 3 Per Share
2025-05-30Interim Dividend - Rs 3 Per Share
2024-09-23Dividend - Rs 2.50 Per Share
2024-09-23Annual General Meeting
2024-05-31Interim Dividend - Rs 2.50 Per Share
2023-09-14Annual General Meeting/Dividend - Rs 2.50 Per Share
2023-06-09Interim Dividend - Rs 2 Per Share
2022-09-21Annual General Meeting/Dividend - Rs 2 Per Share
2022-05-23Interim Dividend - Rs 2 Per Share
2021-09-20 Annual General Meeting/Dividend - Rs 1.50 Per Share
2021-05-18 Interim Dividend - Rs 1.50 Per Share
2020-09-21 Annual General Meeting/Dividend - Rs 0.40 Per Share
2020-03-12 Interim Dividend - Rs 2.10 Per Share
2019-09-04 Annual General Meeting/Dividend - Rs 2.20 Per Share
2018-09-18 Annual General Meeting/Dividend- Rs 2 Per Share
2017-09-07 Annual General Meeting/Dividend - Rs 1.50 Per Share
2016-10-19 Fv Splt Frm Rs 10 To Rs 20.2000
2016-09-01 Annual General Meeting/Dividend - Rs 3.50 Per Share
2016-02-15 Interim Dividend Rs 2.50 Per Share (Purpose Revised)
2015-10-29 Annual General Meeting/Dividend - Rs 5/- Per Share
2014-12-11Annual General Meeting / Final Dividend - Rs 4/- Per Share
DateTypeWhat it says
2026-09-25Shareholder meetingVoting results.
2026-09-25Shareholder meetingProceedings of Annual General Meeting held on September 25, 2026
2026-09-24Volume querySignificant increase in volume has been observed in Caplin Point Laboratories Limited. The Exchange, in order to ensure that investors have latest rel...
2026-09-24Volume querySignificant increase in volume has been observed in Caplin Point Laboratories Limited. The Exchange, in order to ensure that investors have latest rel...
2026-09-04UpdatesLetter to Shareholders.
2026-09-03UpdatesBusiness Responsibility and Sustainability Reporting (BRSR).
2026-09-03Shareholder meetingNotice of Annual General Meeting to be held on September 25, 2026
2026-09-02Volume querySignificant increase in volume has been observed in Caplin Point Laboratories Limited. The Exchange, in order to ensure that investors have latest rel...
2026-09-01UpdatesReceipt of Good Manufacturing Practices (GMP) Compliance Certification by Caplin One Labs Limited (COL), a subsidiary company, from INVIMA.
2026-09-01Volume querySignificant increase in volume has been observed in Caplin Point Laboratories Limited. The Exchange, in order to ensure that investors have latest rel...
2026-08-21UpdatesCompletion of Unannounced US FDA Inspection at the facility of Caplin Steriles Limited (Company s Subsidiary).
2026-08-19Concall / analyst meetTranscript
2026-08-12Concall / analyst meetLink of Recording
2026-08-12Investor PresentationInvestor Presentation
2026-08-12Director changeChange in Director(s) of the company.
2026-08-12DividendBoard of Directors at its meeting held on August 12, 2026, recommended Final Dividend of Rs. 4 per equity share.
2026-08-12Record DateRecord date for the purpose of Dividend is 18-Sep-2026.
2026-08-12Board meeting outcomeCaplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-30Concall / analyst meetSchedule of meet
2026-06-16Disclosure under SEBI TakeovCaplin Point Laboratories Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of In...
2026-05-22Concall / analyst meetSchedule of meet
2026-05-21Concall / analyst meetTranscript
2026-05-14Concall / analyst meetLink of Recording
2026-05-14Press ReleaseA press release dated May 14, 2026, titled "Receipt of final approval by our subsidiary, Caplin Steriles Limited, from the USFDA for Foscarnet Sodium ...
2026-05-14Record DateRecord date for the purpose of Dividend is 30-May-2026.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Caplin Point Laboratories Ltd?

Caplin Point Laboratories Ltd (CAPLIPOINT) has a market capitalisation of Rs 20,858 Cr. at the 2026-10-01 close.

What is the P/E ratio of Caplin Point Laboratories Ltd?

Caplin Point Laboratories Ltd trades at a P/E of 31.4 on trailing twelve-month profit, at the 2026-10-01 close.

What were Caplin Point Laboratories Ltd's latest quarterly results?

In the Jun 2026 quarter, Caplin Point Laboratories Ltd sales was Rs 610 Cr (+19.6% vs Jun 2025) and net profit was Rs 179 Cr.

What is the 52-week high and low of Caplin Point Laboratories Ltd?

The 52-week high is Rs 2,990.00 and the 52-week low is Rs 1,500.30.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03